Nature Reviews Drug Discovery contents July 2013 Volume 12 Number 7 pp 485-559

Advertisement
Wondering where to publish your next paper?   Frontiers is a community-oriented open-access publisher and research network. We are driving innovations around peer-review and a whole ecosystem of open science tools   Be a part of the future of research publication
TABLE OF CONTENTS
July 2013 Volume 12 Number 7
Impact Factor 33.078 *	In this issue Comment News and Analysis Research Highlights Reviews Also this month  Featured article: Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease Frank M. Longo & Stephen M. Massa
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
FREE Nature Collection: Chronic Pain This Nature Collection brings together articles that highlight recent advances towards understanding the risk factors and mechanisms that underlie chronic pain, and developing effective, non-addictive treatments for this highly prevalent condition. FREE online until October 2013. Produced with support from The NIH Pain Consortium
In this issue p485 | doi:10.1038/nrd4069 Full Text
Comment: Optimizing the use of CROs by academia and small companies Rachel F. Lane, Lauren G. Friedman, Curtis Keith, Steven P. Braithwaite, Julie A. Frearson, David A. Lowe, Frank M. Longo, Lorenzo M. Refolo, D. Martin Watterson, Katya Tsaioun, Diana W. Shineman & Howard M. Fillit p487 | doi:10.1038/nrd4057 Contract research organizations (CROs) have a key role in drug discovery and development, but processes for evaluating, engaging and managing CRO contracts may not be well established in academic institutions or small companies. Here, we recommend an approach to optimize the execution of drug discovery programmes in such environments. Full Text | PDF
NEWS AND ANALYSIS		Top
New checkpoint inhibitors ride the immunotherapy tsunami Asher Mullard p489 | doi:10.1038/nrd4066 Immunotherapies that target the PD1-PDL1 axis continue to generate solid clinical data, and fresh combination trial results offer tantalizing hints of greater effectiveness to come. PDF
First-in-class insomnia drug on the brink of approval nod Randy Osborne p492 | doi:10.1038/nrd4067 Merck's dual orexin receptor antagonist suvorexant is approaching the regulatory finish line, 15 years after orexins were discovered. PDF
NEWS IN BRIEF Supreme Court rules on DNA patents p494 | doi:10.1038/nrd4072 PDF
Two approvals boost melanoma arsenal p494 | doi:10.1038/nrd4073 PDF
FDA asks for input on antibiotic drug development p494 | doi:10.1038/nrd4074 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q3 2013 Dane Roybal p496 | doi:10.1038/nrd4056 PDF
BIOBUSINESS BRIEFS Deal watch: AbbVie invests in pioneering celiac disease therapy Sarah Crunkhorn p497 | doi:10.1038/nrd4063 PDF
PATENT WATCH United States to tackle patent trolls Charlotte Harrison p498 | doi:10.1038/nrd4070 PDF
AN AUDIENCE WITH David Haslam Mullard Asher p500 | doi:10.1038/nrd4053 The new Chairman of NICE discusses value-based pricing, cost-benefit appraisals of drugs for rare diseases and the organization's expanded remit. PDF
FROM THE ANALYST'S COUCH New hope for dry AMD? James B. Evans & Basharut A. Syed p501 | doi:10.1038/nrd4038 Dry age-related macular degeneration (AMD) is a major cause of vision loss in the elderly. Evans and Syed discuss the pipeline of therapies for dry AMD and the future of the market. PDF
RESEARCH HIGHLIGHTS Top Cardiovascular disease: Rejuvenating the ageing heart p503 | doi:10.1038/nrd4064 PDF Metabolic disorders: Betatrophin boosts β-cells p504 | doi:10.1038/nrd4058 PDF Cancer: IL-22: linking inflammation and cancer p504 | doi:10.1038/nrd4065 PDF Anticancer drugs: Cracking the combination p505 | doi:10.1038/nrd4071 PDF Anticancer drugs: A new approach for blocking KRAS p506 | doi:10.1038/nrd4054 PDF IN BRIEF Target identification: A new target for treating progeria | Clinical trials: Exenatide provides benefit in Parkinson's disease | Neurological disorders: Identifying pathogenic pathways | Cancer: Preserving fertility during chemotherapy PDF Drug Discovery JOBS of the week Research Associate University of Mainz, Institute of Geosciences Post-doctoral Research Fellowship The Johns Hopkins University School of Medicine Senior Research Scientist Memorial Sloan-Kettering Cancer Center (MSKCC) Post-Doctoral Research Position TU Ilmenau Postdoctoral Research Associate Medical University of South Carolina, Department of Neurosciences More Science jobs from Drug Discovery EVENT NGS for Cancer Drug Development 24.09.13 Boston, USA More science events from
REVIEWS		Top
Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease Frank M. Longo & Stephen M. Massa p507 | doi:10.1038/nrd4024 Although neurotrophins could provide benefit in neurological diseases, their therapeutic application is limited by poor pharmacological properties and undesirable pleiotropic actions. Here, Longo and Massa highlight recent progress in the targeting of individual neurotrophin receptors using small-molecule ligands in an effort to overcome these limitations. Abstract | Full Text | PDF | Supplementary information
Strategies for optimizing the response of cancer and normal tissues to radiation Everett J. Moding, Michael B. Kastan & David G. Kirsch p526 | doi:10.1038/nrd4003 More than half of all patients with cancer receive radiation therapy, but normal tissue tolerance to radiation often limits the ability to cure tumours with radiation therapy. Here, Moding, Kastan and Kirsch discuss current approaches and possible future directions for combining radiation therapy with targeted therapies to enhance the probability of tumour cure. Abstract | Full Text | PDF
New anti-inflammatory targets for chronic obstructive pulmonary disease Peter J. Barnes p543 | doi:10.1038/nrd4025 Current treatments for chronic obstructive pulmonary disease (COPD) do not reduce disease progression or suppress chronic inflammation. This Review highlights new therapeutic targets that have been discovered through a better understanding of the underlying inflammation in COPD and provides an update on the development of anti-inflammatory drugs for this disorder. Abstract | Full Text | PDF
Advertisement
SciBX is pleased to present: SciBX Summit on Innovation in Drug Discovery and Development 2013 October 29-30, 2013 The Colonnade Hotel, Boston, MA, USA  Click here for more information or to register for this conference today!
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2012 Journal Citation Report (Thomson Reuters, 2013)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.